Although many researchers have worked to discover ideal biomarkers that can aid early detection of infection and guidance to antimicrobial therapy, as well as evaluation of inflammation severity and prediction of prognosis in various conditions including sepsis syndrome, autoimmune diseases, trauma, cancer, post-operative period, or ischemia [5,6,7,8,9], C-reactive protein (CRP), procalcitonin (PCT), and interleukin (IL)-6 are the inflammatory markers that are widely being performed in clinical practice outside the realm of research [1,2,5,10,11]. This evidence concerns the gene CRP and cancer.